183.76
price down icon0.83%   -1.54
after-market 시간 외 거래: 184.00 0.24 +0.13%
loading
전일 마감가:
$185.30
열려 있는:
$184.49
하루 거래량:
5.16M
Relative Volume:
0.70
시가총액:
$334.73B
수익:
$57.37B
순이익/손실:
$4.20B
주가수익비율:
78.20
EPS:
2.35
순현금흐름:
$15.39B
1주 성능:
-3.72%
1개월 성능:
+0.27%
6개월 성능:
+3.01%
1년 성능:
+7.85%
1일 변동 폭
Value
$182.30
$185.80
1주일 범위
Value
$182.30
$190.61
52주 변동 폭
Value
$163.52
$218.66

애브비 Stock (ABBV) Company Profile

Name
명칭
Abbvie Inc
Name
전화
(847) 932-7900
Name
주소
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Name
직원
55,000
Name
트위터
@abbvie
Name
다음 수익 날짜
2025-04-25
Name
최신 SEC 제출 서류
Name
ABBV's Discussions on Twitter

ABBV을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - General icon
ABBV
Abbvie Inc
183.76 334.73B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
LLY
Lilly Eli Co
770.64 724.64B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
151.32 376.43B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
69.72 352.49B 43.59B 15.04B 10.74B 3.3766
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
117.52 234.21B 53.22B 12.86B 14.85B 6.39

애브비 Stock (ABBV) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-05-14 다운그레이드 Citigroup Buy → Neutral
2025-04-22 개시 Cantor Fitzgerald Overweight
2024-12-10 재개 BofA Securities Neutral
2024-12-05 다운그레이드 Daiwa Securities Outperform → Neutral
2024-11-22 업그레이드 Leerink Partners Market Perform → Outperform
2024-11-15 개시 Wolfe Research Outperform
2024-11-04 업그레이드 Argus Hold → Buy
2024-10-17 개시 Bernstein Mkt Perform
2024-06-05 업그레이드 HSBC Securities Hold → Buy
2024-05-17 개시 Cantor Fitzgerald Overweight
2024-01-29 업그레이드 William Blair Mkt Perform → Outperform
2023-12-18 다운그레이드 HSBC Securities Buy → Hold
2023-12-11 업그레이드 Goldman Neutral → Buy
2023-11-09 개시 Deutsche Bank Hold
2023-10-30 업그레이드 Barclays Equal Weight → Overweight
2023-10-20 재개 UBS Neutral
2023-09-29 개시 Raymond James Outperform
2023-07-25 개시 William Blair Mkt Perform
2023-07-14 개시 HSBC Securities Buy
2023-04-05 다운그레이드 Argus Buy → Hold
2023-03-01 개시 Guggenheim Buy
2023-02-22 다운그레이드 Wolfe Research Outperform → Peer Perform
2023-02-10 업그레이드 SVB Securities Underperform → Market Perform
2022-11-18 개시 Credit Suisse Outperform
2022-11-08 다운그레이드 Societe Generale Buy → Hold
2022-08-01 다운그레이드 Atlantic Equities Overweight → Neutral
2022-05-23 개시 SVB Leerink Underperform
2022-05-06 다운그레이드 Daiwa Securities Outperform → Neutral
2022-04-06 재개 Morgan Stanley Overweight
2022-02-28 다운그레이드 UBS Buy → Neutral
2022-02-03 재확인 BMO Capital Markets Outperform
2022-02-03 재확인 Barclays Equal Weight
2022-02-03 재확인 BofA Securities Neutral
2022-02-03 재확인 Goldman Neutral
2022-01-13 개시 Redburn Buy
2022-01-12 재확인 BMO Capital Markets Outperform
2021-12-09 재개 Wells Fargo Overweight
2021-11-23 업그레이드 Societe Generale Hold → Buy
2021-07-27 재개 Truist Buy
2021-04-07 재개 RBC Capital Mkts Outperform
2020-11-10 재개 Bernstein Outperform
2020-09-29 개시 Berenberg Hold
2020-06-23 업그레이드 Atlantic Equities Neutral → Overweight
2020-06-09 업그레이드 Wolfe Research Peer Perform → Outperform
2020-06-02 업그레이드 Argus Hold → Buy
2020-05-18 재개 BofA/Merrill Neutral
2020-05-12 업그레이드 JP Morgan Neutral → Overweight
2020-05-11 재개 Morgan Stanley Overweight
2020-04-20 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2020-03-23 다운그레이드 Societe Generale Buy → Hold
2020-02-27 개시 Barclays Equal Weight
2020-02-06 개시 Mizuho Buy
2020-01-07 개시 RBC Capital Mkts Sector Perform
2019-12-26 재확인 Cowen Outperform
2019-09-26 업그레이드 Citigroup Neutral → Buy
2019-08-20 업그레이드 Piper Jaffray Neutral → Overweight
2019-06-27 업그레이드 Wolfe Research Underperform → Peer Perform
2019-06-26 업그레이드 SVB Leerink Mkt Perform → Outperform
2019-05-28 개시 Goldman Neutral
2019-04-29 업그레이드 BMO Capital Markets Underperform → Market Perform
모두보기

애브비 주식(ABBV)의 최신 뉴스

pulisher
Jun 18, 2025

AbbVie (NYSE:ABBV) migraine drug update boosts biotech pipeline strength S&P 500 - Kalkine Media

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie (NYSE:ABBV) Announces Positive Phase 3 Results for Migraine Drug Atogepant - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie's migraine drug meets main goal in head-to-head study with topiramate - Reuters

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie's Migraine Drug Achieves Superiority In Preventing Headaches Compared To Generic Treatment In Head To Head Trial - Benzinga

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie’s atogepant achieves superiority in migraine prevention - The Pharma Letter

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention - PharmaLive

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie (ABBV) Sees Success with Migraine Drug Atogepant in Late-Stage Trial - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie Stock (ABBV) Dips: A Buying Opportunity for its 3.55% Dividend Yield? - Daily Chhattisgarh News

Jun 18, 2025
pulisher
Jun 18, 2025

Hidradenitis Suppurativa Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | InflaRx, Novartis, UCB, AbbVie, Pfizer, Amgen, Incyte, CSL Behring - Barchart.com

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie succeeds in late-stage migraine treatment trial (ABBV) - Seeking Alpha

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie’s migraine drug meets main goal of late-stage study - 1470 & 100.3 WMBD

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie (ABBV) Reports Positive Results from Migraine Study | ABBV Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie Reports Positive Topline Results From Phase 3 TEMPLE Study Of Atogepant For Migrane - Nasdaq

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie Announces New Data Demonstrating Atogepant Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention - Investing News Network

Jun 18, 2025
pulisher
Jun 18, 2025

Fibrotic Diseases Treatment Market Top Companies StudyAbbVie - openPR.com

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie’s atogepant shows superior results in migraine prevention trial By Investing.com - Investing.com Canada

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention | ABBV St - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie's migraine drug meets main goal of late-stage study - TradingView

Jun 18, 2025
pulisher
Jun 17, 2025

Here's Why AbbVie (ABBV) Fell More Than Broader Market - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

AbbVie’s $1.6 Billion Break Fee Sidesteps Capital Loss Limit (1) - news.bloombergtax.com

Jun 17, 2025
pulisher
Jun 17, 2025

AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes - Investing News Network

Jun 17, 2025
pulisher
Jun 17, 2025

AbbVie (ABBV) Faces Potential Challenges Amid U.S. Advertising P - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

RFK Jr. plans crackdown on pharma ads in threat to AbbVie's $2 billion marketing strategy - Crain's Chicago Business

Jun 17, 2025
pulisher
Jun 17, 2025

AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For Myelodysplastic Syndromes - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study - Nasdaq

Jun 17, 2025
pulisher
Jun 17, 2025

Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic? - Nasdaq

Jun 17, 2025
pulisher
Jun 17, 2025

AbbVie says Phase 3 Verona trial of venetoclax/azacitidine did not meet endpoint - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

AbbVie's Diversification Strategy Cushions Venetoclax MDS Blow (NYSE:ABBV) - Seeking Alpha

Jun 17, 2025
pulisher
Jun 17, 2025

AbbVie, ADARx Pharmaceuticals Partner to Develop Next-Gen siRNA Therapeutics - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

AbbVie (ABBV) Pipeline Bolstered as FDA Approves Mavyret Label Expansion for Hepatitis C - Insider Monkey

Jun 17, 2025
pulisher
Jun 16, 2025

AbbVie says blood cancer drug fails late-stage trial - Reuters

Jun 16, 2025
pulisher
Jun 16, 2025

Sector Update: Health Care Stocks Retreat Late Afternoon - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Sector Update: Health Care - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie cancer drug misses the mark in trial for new use - Crain's Chicago Business

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie (ABBV) and Genentech Report Phase III Study Results for Venclexta | ABBV Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie (ABBV) Faces Setback in VERONA Study for Venclexta | ABBV Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie stock dips after cancer drug trial setback - TradingView

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie (ABBV) Faces Setback with Leukemia Drug Trial - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie fails in late-stage trial for Roche-partnered blood cancer therapy venetoclax - Seeking Alpha

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie: trial fails in myelodysplastic syndrome - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie's Venetoclax Doesn't Meet Primary Endpoint in Trial for Higher-Risk Myelodysplastic Syndrome Treatment - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Here's Why AbbVie (ABBV) is a Strong Value Stock - Yahoo Finance

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie Says Myelodysplastic Syndrome Phase 3 Trial Failed to Meet Primary Endpoint - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie Provides Update on VERONA Trial for Newly Diagnosed Highe - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie (ABBV) Phase 3 Trial on Myelodysplastic Syndrome Falls Short | ABBV Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie’s venetoclax fails in phase 3 trial for MDS treatment By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

5 Large Drug Stocks That Are Poised to Ride on Sector Recovery - Yahoo Finance

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie Provides Update On VERONA Trial For Newly Diagnosed Higher-Risk Myelodysplastic Syndromes - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie's Phase 3 VERONA Trial Falls Short: Key Results for Venetoclax MDS Treatment Revealed - Stock Titan

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie: Margin Clarity, Dividend Durability Awaited (NYSE:ABBV) - Seeking Alpha

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie, Chicago Cubs step up to plate to hit a cancer research grand slam - Medical Marketing and Media

Jun 16, 2025

애브비 (ABBV) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

애브비 주식 (ABBV) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Stewart Jeffrey Ryan
EVP, CHIEF COMMERCIAL OFFICER
Mar 31 '25
Sale
210.08
58,832
12,359,504
53,234
drug_manufacturers_general NVO
$69.72
price down icon 5.49%
drug_manufacturers_general JNJ
$151.32
price up icon 1.02%
drug_manufacturers_general NVS
$117.52
price up icon 1.51%
drug_manufacturers_general MRK
$80.16
price up icon 1.39%
$272.44
price down icon 5.84%
자본화:     |  볼륨(24시간):